Navigation Links
Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company
Date:3/10/2008

Acquisition Extends Elsevier's Ability to Gather Global Healthcare News and add to it in-Depth Analysis and Commentary That Will Dramatically Increase

Business Value for Customers

PHILADELPHIA, March 10 /PRNewswire-FirstCall/ -- Elsevier, the world's leading publisher of science, technical and health information, announced today that it has acquired Windhover Information Inc., a healthcare business intelligence company that provides analysis and commentary on healthcare business strategy, industry deal making, marketplace trends and medical start-ups.

The acquisition supports Elsevier's e-Health strategy to improve patient healthcare and the business of health in the Pharma business intelligence market. It expands Elsevier's offering of new products and services for Pharma industry professionals by combining innovative technology and industry-leading content to promote faster and better informed planning and management of product portfolios.

"Adding Windhover's expert analysis of the pharmaceutical and medical device industries to our existing regulatory and general business news services and database expands both the depth and breadth of Elsevier's customer offerings," said Brian Nairn, CEO of Elsevier Health Sciences. "Windhover also provides an exciting platform for new products."

Windhover produces authoritative journals such as IN VIVO and the RPM Report, the world's most comprehensive database of healthcare industry transactions (Strategic Transactions Database), and a series of medical-device and biopharmaceutical partnering and strategy conferences. With Windhover, Elsevier will field a team of more than 100 journalists in bureaus covering healthcare developments across the globe.

The acquisition of Windhover is Elsevier's latest in a series of highly synergistic investments in content, workflow tools and e-Health services. Windhover will operate within Elsevier's Pharma Business Intelligence Unit, which includes F-D-C Reports, Inc. (including "The Pink Sheet" and "The Gray Sheet") and Inteleos, a powerful drug development database.

"Elsevier is one of the few companies as dedicated to covering the business of healthcare as Windhover is," said Roger Longman and David Cassack, Managing Partners and co-founders of Windhover. "We're proud to align with The Pink Sheet and other F-D-C Reports products and provide growth opportunities for our staff."

Terms of the acquisition are not being disclosed.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as Science Direct. (http://www.sciencedirect.com/), MDConsult (http://www.mdconsult.com/), Nursing Consult (http://www.nursingconsult.com/) Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Tom Reller

Director of Corp. Relations, Elsevier

+1-212-462-1912

T.Reller@Elsevier.com


'/>"/>
SOURCE Elsevier
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ScienceDirect to Host French-Language Journals from Elsevier Masson
2. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
3. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
4. Setaram Inc. Acquires Hy-Energy LLC
5. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
6. Linc Facility Services Acquires Morse Medical
7. Acrongenomics Acquires Equity Stake in Molecular Vision
8. Inverness Medical Innovations Acquires ParadigmHealth
9. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
10. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
11. Raptor Pharmaceuticals Acquires Orphan Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/23/2017)... Feb. 23, 2017 ... except per share data, unaudited)Three Months Ended December 31,Twelve ... Revenue $       ... 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  756025%297303(2)%Vimizim ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... Baltimore, Maryland (PRWEB) , ... ... ... firm, PathSensors, Inc., announced today that in a published evaluation of multiple ... (PNNL), a U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection ...
Breaking Biology Technology:
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
Breaking Biology News(10 mins):